Loading clinical trials...

Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor | Clinical Trials | Clareo Health

COMPLETEDNA

Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor

NCT02842333•Centre Hospitalier Universitaire de Besancon

View on ClinicalTrials.gov

Summary

The investigators recently identified promiscuous HLA-DR-derived epitopes from the human telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study tumor-specific CD4+ T cell responses. The aim of this prospective preliminary study is to evaluate the presence of UCP-specific Th1 responses in patients in complete remission of CML two years after end of Tyrosine Kinase Inhibitor (TKi) treatments.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•For cohort A :
•* patient with chronic myelogenous leukemia in chronic phase in deep molecular response (MR4.0) persistent for 2 years or more after end of TKi treatments
•* patient with total cessation of TKi treatment
•* signed written informed consent
•For cohort B :
•* patient with chronic myelogenous leukemia in chronic phase, for whom a diagnosis of relapse was increased 1 year or less after stopping treatment with TKIs (inclusion of patient under TKi treatment after relapse is possible).
•* signed written informed consent

Exclusion Criteria

•patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (corticoids ≤ 10 mg/day is allowed)
•active autoimmune diseases, HIV, hepatitis C or B virus
•patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study.
•patient under guardianship, curator or under the protection of justice.

Locations (4)

Centre Hospitalier Régional Universitaire de Besançon

Besançon, France

CHU de Dijon

Dijon, France

CHU de Nice

Nice, France

Hôpital Saint-Louis

Paris, France

Key Dates

Start Date

May 1, 2016

Primary Completion Date

October 6, 2020

Completion Date

October 6, 2020

Last Updated

May 25, 2025

Enrollment

ACTUAL participants

Conditions

Chronic Leukemia

Interventions

Additional biological samples

OTHER

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

NCT07445984

Chronic LeukemiaAcute Leukemia+3 more

View study

ACTIVE_NOT_RECRUITING

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

NCT06297161

Chronic Leukemia Myelogenous

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 25, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor

Inclusion Criteria

Exclusion Criteria

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Fungemia in Hematologic Malignancies

Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells

Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor